Header cover image

Australian (ASX) Biotech Industry Analysis

UpdatedNov 27, 2021
DataAggregated Company Financials
Companies39
  • 7D-1.5%
  • 3M0.5%
  • 1Y4.1%
  • YTD11.1%

Over the last 7 days, the Biotech industry has dropped 1.5%, driven by a pullback from CSL of 1.1%. Meanwhile, Biotron actually outperformed within the industry, gaining 76% in the last week. This takes the industry's 12 month performance to a gain of 4.1%.

Industry Valuation and Performance

Has the Australian Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Sat, 27 Nov 2021AU$154.6bAU$14.6bAU$2.8b43x
Mon, 25 Oct 2021AU$147.1bAU$14.0bAU$2.6b42.4x
Wed, 22 Sep 2021AU$153.9bAU$14.4bAU$2.7b43.2x
Fri, 20 Aug 2021AU$150.1bAU$14.0bAU$2.6b44x
Fri, 04 Jun 2021AU$142.6bAU$13.5bAU$2.8b39.9x
Mon, 08 Mar 2021AU$128.5bAU$13.1bAU$3.0b34.6x
Thu, 10 Dec 2020AU$144.9bAU$13.5bAU$2.9b29.8x
Wed, 02 Sep 2020AU$138.9bAU$13.5bAU$2.7b42.7x
Sat, 06 Jun 2020AU$132.9bAU$14.9bAU$3.0b37.5x
Tue, 10 Mar 2020AU$146.5bAU$12.9bAU$2.5b49.2x
Mon, 02 Dec 2019AU$135.4bAU$13.1bAU$2.6b64.4x
Thu, 05 Sep 2019AU$114.5bAU$12.3bAU$2.4b56.5x
Sun, 09 Jun 2019AU$97.9bAU$12.0bAU$2.3b67.4x
Sat, 02 Mar 2019AU$91.5bAU$11.8bAU$2.2b57.5x
Tue, 04 Dec 2018AU$83.4bAU$11.3bAU$2.2b44.4x
PE Ratio

44.4x

Total Market Cap: AU$83.4bTotal Earnings: AU$2.2bTotal Revenue: AU$11.3b0%0%0%3 Year10 Year
201920202021

Current Industry PE: There are only 3 profitable companies in this industry, so there is insufficient data to make an industry-wide assessment of PE.

Past Earnings Growth: The earnings for companies in the Biotechs industry have grown 8.4% per year over the last three years, and revenues for these companies have grown 8.8% per year. This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Australian Biotech industry?

Biotech-1.47%

Industry PE: Investors are most optimistic about the Biotech industry, which is trading close to its 3-year average PE ratio of 45.9x. However analysts are expecting annual earnings growth of 12%, which is lower than the prior year's growth of 39% per year. So the market might believe that analysts are underestimating future growth.

Forecasted Growth: Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 12% over the next 5 years. However this is lower than its past earnings growth rate of 39% per year.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company7D1YValuation
BIT Biotron75.5%+AU$26.0m3.6%PS41.3x
PAR Paradigm Biopharmaceuticals3.3%+AU$16.1m-24.5%PS27750x
BNO Bionomics8.3%+AU$10.2m0%PS142.9x
ARX Aroa Biosurgery0.9%+AU$3.4m-9.4%PS13.3x
RGS Regeneus2.9%+AU$612.9k-34.5%PE8x
Simply Wall St
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

BIT

AU$0.086

Biotron

7D

75.5%

1Y

3.6%

CSL

AU$312.00

CSL

7D

-1.1%

1Y

3.0%

KZA

AU$1.38

Kazia Therapeutics

7D

-9.8%

1Y

0.7%

RGS

AU$0.072

Regeneus

7D

2.9%

1Y

-34.5%

IMM

AU$0.49

Immutep

7D

-9.3%

1Y

84.9%

IMU

AU$0.51

Imugene

7D

-9.7%

1Y

410.0%